SUO 2017: Identifying The Rate And Risks Of Chronic Kidney Disease Development After Cytoreductive Nephrectomy

Washington, DC ( Cytoreductive nephrectomy has been shown to improve overall survival in patients with metastatic renal cell carcinoma (mRCC). At today’s 2017 SUO winter meeting poster session, Dr. Martin and colleagues presented their research identifying the rate and risks of chronic kidney disease development after cytoreductive nephrectomy.

SUO 2017: Hospital Volume and Short-Term Outcomes after Cytoreductive Nephrectomy

Washington, DC ( Dr. Xia and colleagues presented results from their study assessing hospital volume and short-term outcomes after cytoreductive nephrectomy. Indeed, cytoreductive nephrectomy is considered a treatment option for selected patients with metastatic renal cell carcinoma (mRCC), although it can be complex with significant perioperative morbidities. To date, there have been no studies reporting on volume-outcome associations in the CN setting; the current study’s objective was to explore this potential relationship.

SUO 2017: Cytoreductive Nephrectomy In Patients With Metastatic Renal Cell Carcinoma And Tumor Thrombus – Trends And Effect On Overall Survival

Washington, DC ( Dr. Lenis and colleagues presented their population-based research this afternoon at the 2017 SUO annual winter meeting in Washington DC, discussing trends and effect on overall survival for patients undergoing cytoreductive nephrectomy for patients with concomitant tumor thrombus.

SUO 2017: Perioperative Outcomes of Aspirin Use in Partial Nephrectomy

Washington, DC ( Increasing cardiovascular disease has led to increased use of anti-platelet therapy in a patient population who often require urologic surgery. Dr. Ingham and colleagues presented their research assessing perioperative outcomes of aspirin use in partial nephrectomy patients. The objective of the study was to assess perioperative outcomes for those undergoing partial nephrectomy while taking or not taking perioperative aspirin.

SUO 2017: Renal Medullary Carcinoma and Collecting Duct Carcinoma of the Kidney

Washington, DC ( Collecting duct carcinoma and renal medullary carcinoma are rare subtypes of renal cell carcinoma with poor survival. Dr. Beksac and colleagues presented their population-level analysis assessing Renal Medullary Carcinoma and Collecting Duct Carcinoma of the Kidney, a Clinicopathological and Survival Analysis from the National Cancer Database.  Indeed, there is no standard way to treat these subtypes in advanced stages. The objective of this study was to characterize the demographic, clinical, pathologic profile and overall survival (OS) of patients diagnosed with collecting duct carcinoma and renal medullary carcinoma of the kidney.

SUO 2017: Validation of The Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer

Washington, DC ( Dr. Ghanaat and colleagues presented their validation of a preoperative nomogram predicting 12-year probability of metastatic renal cancer. The authors previously published a predictive model to determine the preoperative risk of metastatic recurrence in localized renal cell carcinoma [1], as size of the primary renal mass, evidence of lymphadenopathy or necrosis on preoperative imaging and the mode of presentation were important predictors for the subsequent development of metastases. The objective of this study was to validate this initial nomogram and interrogate the additive value of somatic mutations in a subcohort with available genomic data. 

SUO 2017: Keynote-564: Phase 3, Double-blind, Placebo-controlled Trial Of Pembrolizumab As Adjuvant Treatment For Renal Cell Carcinoma

Washington, DC ( Dr. Zhang and colleagues presented their phase III trial design of adjuvant pembrolizumab for patients with renal cell carcinoma (RCC) at this afternoon’s SUO 2017 annual meeting poster session. Effective adjuvant therapies for patients with RCC at risk of recurrence after nephrectomy are lacking, and previous adjuvant therapy trials utilizing TKIs have proven disappointing [1-3]. Programmed death ligand 1 (PD-L1) and 2 (PD-L2) expression predicts poor prognosis in RCC. Programmed death 1 (PD-1) inhibitors have demonstrated activity in metastatic RCC [4], and PD-1 may represent a novel therapeutic target in the adjuvant setting. Pembrolizumab is a PD-1 inhibitor that directly blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The objective of this randomized, double-blind, placebo-controlled phase III trial is to evaluate the efficacy and tolerability of pembrolizumab as adjuvant therapy in patients with high-risk RCC following nephrectomy and/or metastasectomy.
Page 1 of 5

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.